2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2217

Adherence to Drug Therapy in Patients with Fibromyalgia
Abstract Number: 2218

Do Some Patients with Distal Upper Limb Pain Benefit More Than Others from Advice to Remain Active?
Abstract Number: 2219

Clinical and Radiological Characteristics of Patients with Adhesive Capsulitis and Shoulder Impingement Syndrome
Abstract Number: 2220

Impact of Fibromyalgia on DAS28 in Patients with Rheumatoid Arthritis
Abstract Number: 2221

Recognition of Secondary Fibromyalgia Using an Index of 3 Components of the Multi-Dimensional Health Assessment Questionnaire: 90% Agreement with ACR Criteria for Fibromyalgia
Abstract Number: 2222

Tai Chi Is More Effective Than Aerobic Exercise in Treating Fibromyalgia: A Randomized Controlled Trial
Abstract Number: 2223

Can Fibromyalgia be Empirically Defined By the Number of Pain Locations Plus Symptoms?
Abstract Number: 2224

Influence of Caffeine on Opioid Analgesics in Fibromyalgia
Abstract Number: 2225

Treatment Outcomes of Newly and Formerly Diagnosed Patients with Fibromyalgia after Fibromyalgia Treatment Program
Abstract Number: 2226

Independent and Combined Association of Overall Physical Fitness and Subjective Well-Being Components with Fatigue in Fibromyalgia
Abstract Number: 2227

Sustained Remission and Relapse Rate after Non-Conventional DMARD Withdrawal in Patients with Rheumatoid Arthritis
Abstract Number: 2228

Real-World Cost of Treating Inadequate Responders to Anti-Tumor Necrosis Factor Therapy
Abstract Number: 2229

Economic Burden of Rheumatoid Arthritis Is Higher for ACPA-Positive Patients
Abstract Number: 2230

Models Using Claims-Based Administrative Data Are Poor Predictors of Rheumatoid Arthritis Disease Activity in VA Rheumatoid Arthritis (VARA) Patients
Abstract Number: 2231

Change in Health Care Utilization after Etanercept Initiation in Patients with Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].